NivolumabGrade 3 immune-related hepatitis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1709卷 / 1期

关键词：

D O I：

10.1007/s40278-018-48596-z

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：185 / 185

相关论文

共 50 条

[1] Denosumab/nivolumabGrade 2 immune-related rheumatological toxicity and hypopituitarism: case report
[J]. Reactions Weekly, 2022, 1891 (1) : 118 - 118
[2] PembrolizumabSevere immune-related hepatitis: case report
[J]. Reactions Weekly, 2020, 1788 (1) : 191 - 191
[3] Ipilimumab/nivolumabGrade 3 autoimmune hepatitis: case report
[J]. Reactions Weekly, 2022, 1929 (1) : 359 - 359
[4] NivolumabBilateral vocal cord paralysis, immune-related hepatitis, and immune-related colitis: case report
[J]. Reactions Weekly, 2021, 1863 (1) : 275 - 275
[5] Bevacizumab/ipilimumab/pembrolizumabBrain haemorrhage, immune-related hypophysitis and immune-related hepatitis: case report
[J]. Reactions Weekly, 2017, 1633 (1) : 125 - 125
[6] Ampicillin/cemiplimab/fluconazoleHepatotoxicity and immune-related hepatitis: case report
[J]. Reactions Weekly, 2020, 1822 (1) : 36 - 36
[7] Ipilimumab/nivolumab/pembrolizumabAcute hepatitis and immune-related colitis: case report
[J]. Reactions Weekly, 2019, 1742 (1) : 134 - 134
[8] AntineoplasticsLack of efficacy, immune-related hyperthermia and immune-related pneumonitis: case report
[J]. Reactions Weekly, 2021, 1864 (1) : 43 - 43
[9] Immunosuppressants/pembrolizumabImmune-related hepatitis, immune-related retinopathy and lack of efficacy: case report
[J]. Reactions Weekly, 2023, 1958 (1) : 281 - 281
[10] NivolumabSymptomatic immune-related pancreatitis: case report
[J]. Reactions Weekly, 2016, 1615 (1) : 150 - 150

← 1 2 3 4 5 →